Home » Stocks » Pfizer

Pfizer (PFE) Stock Price & AI Analysis

$23.04

-$0.48

(2.04%)

Pharmaceuticals

NYSE

May 22, 3:53 PM EDT

Market Cap.
130.99B
Volume
42.92M
Avg. Volume
54.34M
Target Price
$28.26
52W Range
20.92 - 31.54

RSI (14)
48.93
Beta
0.53
PEG Ratio
SMA 20
-0.4400%
SMA 50
-2.87%
SMA 200
-12.94%

Insider Owner
0.18%
Insider Trans
0.17%
Institution Owner
67.07%
Institution Trans
-1.56%
Short Interest
115.16%
EPS next Y
2.81

Pfizer Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Analyst recommendations

Pfizer | Latest news

MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots

Shares of prominent COVID-19 vaccine-makers Moderna MRNA, Pfizer PFE and BioNTech BNTX rose...

Zacks - 1 day ago

Citi Maintains a Hold Rating on Pfizer (PFE) Amidst Pricing Policy Headwinds

On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE),...

Insider Monkey - 23 hours ago

Pfizer Inc. (PFE) Inks $6 Billion Cancer Drug Licensing Agreement with China’s...

On May 19, Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at...

Insider Monkey - 3 days ago

PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?

Merck MRK and Pfizer PFE are leading pharmaceutical companies with strong product and pipeline...

Zacks - 3 days ago

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good...

Zacks - 6 days ago

Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal

Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc....

Insider Monkey - 1 day ago

5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an...

Zacks - 8 hours ago

BMO Capital Maintains Buy Rating on Pfizer (PFE) Stock

On May 20, BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and...

Insider Monkey - 2 days ago

The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...

Zacks - 1 day ago

Cigna takes different approach with GLP-1s, more favorable for Eli Lilly By...

Cigna takes different approach with GLP-1s, more favorable for Eli Lilly

Investingcom - 2 hours ago